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What’s been updated: 
• COVID-19 Convalescent Plasma (152) 
o Safety concerns addition 
 
Highlights: 
• There are no specific therapies approved by the U.S. Food and Drug Administration (FDA) for 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes 
coronavirus disease 2019 COVID-19. Several agents are being used under clinical trial and 
compassionate use protocols based on in vitro activity (against SARS-CoV-2 or related viruses) 
and on limited clinical experience. Efficacy has not been established for any drug therapy. 
• Antimicrobials with potential activity against SARS-CoV-2: 
o Remdesivir – Investigational antiviral available under an FDA Emergency Use 
Authorization (EUA); several large clinical trials are underway with preliminary data 
suggesting clinical benefit. 
o Chloroquine – In vitro and limited clinical data suggest potential benefit; FDA EUA issued 
to facilitate availability. 
o Hydroxychloroquine – In vitro and limited clinical data suggest potential benefit; FDA EUA 
issued to facilitate availability. 
o Lopinavir; Ritonavir – Role in the treatment of COVID-19 is unclear. Preclinical data 
suggested potential benefit; however, more recent data has failed to confirm. 
o Favipiravir – Investigational use is being studied. 
 
• Adjunctive / supportive care: 
o Anticoagulation – Venous thromboembolism prophylaxis with low molecular weight heparin 
(LMWH) recommended for all hospitalized patients. 
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o Azithromycin – Used in some protocols based on theoretical mechanism and limited 
preliminary data as adjunct therapy.  
o Bronchodilators – No routine role for inhaled bronchodilators in the management of 
COVID-19; metered-dose inhalers (MDI) preferred over nebulized therapy due to the risk 
of viral transmission. 
o Corticosteroids – Not recommended for viral pneumonia; use may be considered for 
patients with refractory shock or acute respiratory distress syndrome. 
o COVID-19 convalescent plasma – Investigational use is being studied. 
o Fibrinolytics – Severe COVID-19 infection is associated with coagulopathy; fibrin 
deposition in the pulmonary microvasculature is a causative factor in the development of 
ARDS. 
o Immunomodulating agents [Interleukin Receptor Antagonists, Janus Kinase (JAK) 
inhibitors] – Used in some protocols based on theoretical mechanisms and limited 
preliminary data as adjunct therapy.  
o Inhaled pulmonary vasodilators – No evidence for routine in acute respiratory failure; use 
may be considered in specific patients with acute respiratory distress syndrome (ARDS) as 
a temporizing measure. 
o NSAIDS – The FDA continues to investigate the use of NSAIDs; concern for potential 
worsening of COVID-19 symptoms has been suggested, but confirmatory clinical data is 
lacking. 
 
According to the World Health Organization (WHO), the Centers for Disease Control and Prevention 
(CDC), the FDA, and the National Institutes of Health (NIH), there are currently no medications or 
vaccines proven to be effective for the treatment or prevention of SARS-CoV-2. (1) (2) (3) (133) 
 
Generally, pharmacologic treatment is not recommended for young, healthy patients with mild 
symptoms and no underlying comorbid conditions.(12) (13) 
 
Antimicrobials with potential activity against SARS-CoV-2: 
Remdesivir (GS-5734):  
• Classification: Investigational Nucleoside Analogue 
• Rationale for Use: Remdesivir is a broad-spectrum antiviral with in vitro activity against 
coronaviruses.(10) (14) (38) (39) (41) (42) (43) (44) 
• Mechanism of Action: Remdesivir is a monophosphoramidate prodrug of remdesivir-
triphosphate (RDV-TP), an adenosine analog that acts as an inhibitor of RNA-dependent RNA 
polymerases (RdRps). Remdesivir-TP competes with adenosine-triphosphate for incorporation 
into nascent viral RNA chains. Once incorporated into the viral RNA at position i, RDV-TP 
terminates RNA synthesis at position i+3. Because RDV-TP does not cause immediate chain 
termination (i.e., 3 additional nucleotides are incorporated after RDV-TP), the drug appears to 
evade proofreading by viral exoribonuclease (an enzyme thought to excise nucleotide analog 
inhibitors).(10) (14) (38) (39) (41) (42) (43) (44) (45) 
• FDA Emergency Use Authorization (EUA): (146) 
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o Remdesivir is not an FDA-approved medication. 
o The EUA allows for the emergency use of remdesivir to treat suspected or laboratory 
confirmed COVID-19 in adults and children hospitalized with severe disease. 
o The EUA defines severe COVID-19 disease as patients with an oxygen saturation 
(SpO2) of 94% or less on room air, or requiring supplemental oxygen, or requiring 
mechanical ventilation or extracorporeal membrane oxygenation (ECMO).  
• Evidence / Experience: 
o The NIH COVID-19 treatment guidelines recommend the use of remdesivir in 
hospitalized patients with severe COVID-19; however, its use in patients with mild or 
moderate COVID-19 is not recommended outside of clinical trials.(133)  
o Preliminary data from a Phase III trial [i.e., Adaptive COVID-19 Treatment Trial (ACTT)] 
suggest remdesivir may provide clinical benefit in the treatment of hospitalized patients 
with advanced COVID-19 and lung involvement.(145) (146) 
 The median time to recovery was 11 days in the remdesivir-treated group 
compared to 15 days in placebo group (hazard ratio: 1.31; 95% CI: 1.12 to 
1.54, p < 0.001). 
 Mortality was 8% for the remdesivir group vs. 11.6% for the placebo group (p = 
0.059) 
o A randomized, double-blind, placebo-controlled, multicenter trial evaluating efficacy 
and safety of remdesivir in SARS-CoV-2 infected hospitalized adults (concurrent 
treatment with corticosteroids, interferons, and lopinavir; ritonavir was permitted).(150) 
 No difference between remdesivir (n = 158) and placebo (n = 79) in the time to 
clinical improvement (median, 21 vs. 23 days; hazard ratio, 1.23; 95% CI: 0.87 
to 1.75). 28-day mortality was similar between remdesivir (14%) and placebo 
(13%) (95% CI: -8.1 to 10.3). 
 Adverse events reported in 66% of remdesivir patients and 64% of placebo 
patients. Remdesivir was stopped early in 12% of patients due to adverse 
events. 
o Preliminary data from open-label compassionate use in patients with severe disease 
was analyzed.(124) 
 Clinical improvement, as defined by improvement in oxygen support, was 
reported in 36 of 53 patients (68%). 
 Clinical improvement was less frequent in those receiving invasive ventilation 
and in patients 70 years or older. 
o Several clinical trials evaluating the efficacy of remdesivir in patients infected with 
SARS-CoV-2 are currently being conducted.(132) 
• Safety Concerns: (133) (146) 
o Caution in patients with renal impairment due to formulation with sulfobutyl ether beta-
cyclodextrin sodium (SBECD) 
o Infusion-related reactions 
o Risk for elevated hepatic enzymes 
Chloroquine: 
• Classification: Antimalarial 
• Rationale for Use: Chloroquine has in vitro activity against SARS-CoV-2 and may have 
immunomodulating properties.(13) (14) (15) (17)  
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• Mechanism of Action: Mechanisms may include inhibition of viral enzymes or processes such 
as viral DNA and RNA polymerase, viral protein glycosylation, virus assembly, new virus 
particle transport, and virus release. Other mechanisms may also involve ACE2 cellular 
receptor inhibition, acidification at the surface of the cell membrane inhibiting fusion of the 
virus, and immunomodulation of cytokine release.(14) (15) (29) (30) (31) (32) (33) 
• FDA Emergency Use Authorization (EUA): (66) (67) 
o Chloroquine is not FDA-approved for the treatment of COVID-19. 
o EUA is to facilitate the availability of chloroquine during the COVID-19 pandemic to 
treat patients for whom a clinical trial is not available, or participation is not feasible. 
o The EUA states treatment is for adult and adolescent patients weighing 50 kg or more 
who are hospitalized with COVID-19. 
o Authorized chloroquine is limited to product supplied from the Strategic National 
Stockpile (SNS) and will be distributed to authorized heath care systems and providers. 
• Evidence / Experience: 
o Due to a lack of clinical data, the NIH COVID-19 treatment guidelines do not give 
recommendations for or against the use of chloroquine; however, if used, guidelines 
advise monitoring for adverse events, including QT interval prolongation. The NIH 
recommends against the use of high-dose, twice-daily chloroquine due to a higher risk 
of toxicities.(133) 
o Pre-clinical data in vitro suggest chloroquine has activity has activity against SARS-
CoV-2.(13) (14) (15) 
o There have been reports of potential benefit in inhibiting the exacerbation of 
pneumonia patients with SARS-CoV-2 infection; however, specific data are not 
available.(13)  
o Some protocols include recommendations for use.(12) (21) (22) 
o Additional data regarding clinical efficacy for COVID-19 are being evaluated.(16) (31) 
• Safety Concerns: (46) (49) 
o Use in COVID-19 patients outside of clinical trials or in a nonhospital setting is not 
recommended due to the potential for serious adverse events and drug 
interactions.(141) 
o Risk of cardiac arrhythmias (e.g., QT prolongation) 
 Seriously ill patients with comorbidities have an increased risk of serious 
arrhythmias.(125) 
 Avoid other QT prolonging agents whenever feasible.(125) 
 In a parallel, double-masked, randomized clinical trial (n = 81), two doses of 
chloroquine were analyzed (600 mg PO twice daily for 10 days vs. 450 mg PO 
twice daily on day 1 then 450 mg PO once daily for 4 days).(126) 
• The high-dose group had a higher incidence of QT interval greater than 
500 milliseconds (18.9%) compared with the low-dose group (11.1%); 
therefore, the study was unmasked and all patients were reverted to the 
low-dose group. 
o Risk of retinal damage, especially with long term use 
o Caution in patients with G6PD deficiency 
o Caution in diabetics 
o Significant drug interactions  
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Hydroxychloroquine: 
• Classification: Antimalarial 
• Rationale for Use: Hydroxychloroquine has in vitro activity against SARS-CoV-2 and may have 
immunomodulating properties.(13) (14) (15) (17)  
• Mechanism of Action: Mechanisms may include inhibition of viral enzymes or processes such 
as viral DNA and RNA polymerase, viral protein glycosylation, virus assembly, new virus 
particle transport, and virus release. Other mechanisms may also involve ACE2 cellular 
receptor inhibition, acidification at the surface of the cell membrane inhibiting fusion of the 
virus, and immunomodulation of cytokine release.(14) (15) (29) (30) (31) (32) (33) 
• FDA Emergency Use Authorization (EUA): (66) (68) 
o Hydroxychloroquine is not FDA-approved for the treatment of COVID-19. 
o EUA is to facilitate the availability of hydroxychloroquine during the COVID-19 
pandemic to treat patients for whom a clinical trial is not available, or participation is not 
feasible. 
o The EUA states treatment is for adult and adolescent patients weighing 50 kg or more 
who are hospitalized with COVID-19. 
o Authorized hydroxychloroquine is limited to product supplied from the Strategic 
National Stockpile (SNS) and will be distributed to authorized heath care systems and 
providers. 
• Evidence / Experience: 
o Due to a lack of clinical data, the NIH COVID-19 treatment guidelines do not give 
recommendations for or against the use of hydroxychloroquine; however, if used, 
guidelines advise monitoring for adverse events including QT interval prolongation 
(133) 
o Pre-clinical in vitro data suggest hydroxychloroquine has activity against SARS-CoV-
2.(12) (15) (17) (18) (21) 
o One in vitro study suggests that hydroxychloroquine may be more potent than 
chloroquine.(15) 
 Hydroxychloroquine exhibited a higher in vitro antiviral effect compared to 
chloroquine when drug was added prior to the viral challenge. 
• The EC50 values for chloroquine were greater than 100 microM at 24 
hours and 18.01 microM at 48 hours. 
• The EC50 values for hydroxychloroquine were 6.25 microM at 24 hours 
and 5.85 microM at 48 hours. 
o An open-label, non-randomized clinical trial compared hydroxychloroquine treatment (n 
= 26) to an untreated negative control group.(27) 
 Preliminary data showed the proportion of patients that had negative PCR 
results significantly differed between treated patients and untreated controls. 
 On day 6, 70% of hydroxychloroquine-treated patients were virologically cured 
compared to 12.5% in the untreated control group. 
o A parallel-group, randomized trial (n = 62) of hospitalized patients with non-severe 
COVID-19 compared 5 days of hydroxychloroquine to standard treatment.(69) 
 Fever recovery time was shortened in the hydroxychloroquine group (2.2 days) 
compared to standard therapy (3.2 days). 
 Cough recovery time was shortened in the hydroxychloroquine group (2 days) 
compared to standard therapy (3.1 days). 
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o A prospective review assessed virologic and clinical outcomes of 11 hospitalized 
patients who received hydroxychloroquine and azithromycin.(88) 
 Within 5 days, 1 patient died, 2 were transferred to the ICU, and 1 patient had 
therapy discontinued due to QT prolongation. 
 Nasopharyngeal swabs were still positive for SARS-CoV-2 in 8 of 10 patients 5 
to 6 days after treatment initiation. 
o In a preliminary report of a multicenter, parallel, open-label, randomized trial in 150 
adult hospitalized patients, hydroxychloroquine (n = 75) was added to standard 
therapy.(127)  
 The overall 28-day negative viral conversion rate was not different between the 
two groups (85.4% hydroxychloroquine vs 81.3% control, p = 0.341).  
 Negative conversion rates on days 4, 7, 10, and 21 were also similar between 
the groups.  
 There was no difference in the 28-day symptom alleviation rate; however, a 
significant efficacy on symptom alleviation was observed when the confounding 
effects of antiviral agents were removed in the post-hoc analysis.  
 Additionally, there was a greater reduction in C-reactive protein (CRP) (6.986 
mg/L hydroxychloroquine vs 2.723 mg/L control, p = 0.045) and a nonsignificant 
increase in recovery of lymphopenia in the hydroxychloroquine group.  
 Adverse events were reported in 8.8% of the control group and 30% of the 
hydroxychloroquine group. 
o Preliminary data from a retrospective analysis (n = 368) assessed the use of either 
hydroxychloroquine (n = 97) or hydroxychloroquine plus azithromycin (n = 133) in 
addition to standard of care compared to standard of care alone (n = 158).(134) 
 The cohort consisted of only men in the Veterans Health Administration medical 
centers with a median age older than 65 years, the majority of whom were 
black. 
 The primary outcomes were death and the need for mechanical ventilation. 
• Rates of death in the hydroxychloroquine group, the hydroxychloroquine 
plus azithromycin group, and the standard treatment group were 27.8%, 
22.1%, and 11.4%, respectively. Compared to standard therapy, the risk 
of death from any cause was higher in the hydroxychloroquine group 
(adjusted HR 2.61; 95% CI, 1.10 to 6.17; p = 0.03), but not in the 
hydroxychloroquine plus azithromycin group (adjusted HR 1.14; 95% CI, 
0.56 to 2.32; p = 0.72). 
• Rates of ventilation in the hydroxychloroquine group, the 
hydroxychloroquine plus azithromycin group, and the standard 
treatment group were 13.3%, 6.9%, and 14.1%, respectively. Compared 
to standard therapy, the risk of ventilation was similar in both the 
hydroxychloroquine group (adjusted HR 1.43; 95% CI, 0.53 to 3.79; p = 
0.48) and the hydroxychloroquine plus azithromycin group (adjusted HR 
0.43; 95% CI, 0.16 to 1.12; p = 0.09). 
o An observational trial (n = 1,376) examined the association between 
hydroxychloroquine use and intubation or death at a large medical center.(149) 
 Hydroxychloroquine was not associated with a significantly higher or lower risk 
of intubation or death (HR 1.04; 95% CI, 0.82 to 1.32); similar results were 
noted when adjusted for propensity score.  
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 Hydroxychloroquine-treated patients were more severely ill at baseline.  
 Due to wide confidence intervals and the observational nature of the trial, the 
authors stated that the results should not be utilized to rule out either benefit or 
harm of hydroxychloroquine and suggested further randomized clinical trials to 
test efficacy. 
o An observational study of 1,438 hospitalized patients assessed mortality in patients 
receiving hydroxychloroquine (n = 271), azithromycin (n = 211), or both (n = 735) 
compared to patients who received neither of these agents (n = 221).(155) 
 There was no difference in mortality in patients treated with hydroxychloroquine 
(HR 1.08; 95% CI, 0.63 to 1.85), azithromycin (HR 0.56; 95% CI, 0.26 to 1.21), 
or both (HR 1.35; 95% CI, 0.76 to 2.4) compared with no use of these agents. 
 In logistic models, cardiac arrest was significantly more likely in patients 
receiving hydroxychloroquine plus azithromycin (OR 2.13; 95% CI, 1.12 to 4.05) 
compared to patients receiving neither drug; however, this was not the case in 
patients receiving either drug alone.  
 In adjusted logistic regression models, there were no significant differences in 
the relative likelihood of abnormal electrocardiogram findings. 
 Patient receiving hydroxychloroquine with or without azithromycin were overall 
sicker on presentation. 
o Some protocols have recommendations for use.(12) (21) 
o Additional data regarding clinical efficacy for COVID-19 are being evaluated.(16) (31) 
• Safety Concerns: (47) (49) 
o Use in COVID-19 patients outside of clinical trials or in a nonhospital setting is not 
recommended due to the potential for serious adverse events and drug 
interactions.(141) 
o Risk of cardiac arrhythmias (e.g., QT prolongation) 
 Seriously ill patients with comorbidities have an increased risk of serious 
arrhythmias.(125) 
 Avoid other QT prolonging agents whenever feasible.(125) 
o Risk of retinal damage, especially with long term use 
o Caution in patients with G6PD deficiency 
o Caution in diabetics 
o Significant drug interactions 
 
Lopinavir; Ritonavir: 
• Classification: HIV Protease Inhibitor 
• Rationale for Use: In vitro and animal model studies show potential activity for other 
coronaviruses (SARS-CoV and MERS-CoV).(4) (52) (53) (54) 
• Mechanism of Action: Lopinavir and ritonavir may bind to Mpro, a key enzyme for coronavirus 
replication. This may suppress coronavirus activity.(55) 
• Evidence / Experience: 
o Due to unfavorable pharmacodynamics and negative clinical trial data, the NIH COVID-
19 treatment guidelines recommend against the use of lopinavir; ritonavir or other HIV 
protease inhibitors outside of clinical trials.(133) Similarly, ESICM and SCCM Surviving 
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Sepsis Campaign recommendations suggest against the routine use of lopinavir; 
ritonavir in critically ill adults with COVID-19.(26) 
o Pre-clinical data show activity for other coronaviruses.(4) (52) (53) (54) 
o A randomized, controlled, open-label trial involving hospitalized patients with confirmed 
SARS-CoV-2 infection (n = 199), analyzed treatment with lopinavir; ritonavir.(23) 
 Not associated with a difference from standard of care in the time to clinical 
improvement (median, 16 days versus 16 days; hazard ratio 1.31; 95% CI, 0.95 
to 1.80; p = 0.09); percentages of patients with detectable viral RNA were 
similar; 28 day mortality was also similar (19.2% vs. 25%, respectively).  
o A retrospective cohort study of hospitalized patients reviewing clinical course and risk 
factors for mortality included 29 patients who received lopinavir; ritonavir.(24) 
 No difference was noted in the duration of viral shedding after treatment with 
lopinavir; ritonavir. 
• Safety Concerns: (45) (49) 
o Risk of cardiac arrhythmias (e.g., QT prolongation) 
 Seriously ill patients with comorbidities have an increased risk of serious 
arrhythmias.(125) 
 Avoid other QT prolonging agents whenever feasible.(125) 
o Caution in patients with hepatic disease or hepatitis 
o Significant drug interactions 
 
Favipiravir: 
• Classification: Investigational RNA-Dependent RNA Polymerase Inhibitor 
• Rationale for Use: Favipiravir is a broad-spectrum antiviral with in vitro activity against RNA 
viruses.(14) (18) (75) 
• Mechanism of Action: Favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor 
that inhibits viral RNA synthesis.(14) (18) (75) 
• Evidence / Experience: 
o In a non-randomized, controlled, open-label trial, the efficacy of favipiravir (n = 35) 
in treating patients with laboratory confirmed COVID-19 was compared against 
lopinavir; ritonavir (n = 45); both treatments were given in combination with inhaled 
interferon alpha.(142) 
 Time to viral clearance was shorter for favipiravir (median, 4 days; range, 
2.5 to 9 days) than for lopinavir; ritonavir (median, 11 days; range 8 to 13 
days; p < 0.001). 
 Chest imaging improvement rate at treatment day 14 was 91% for favipiravir 
vs. 62% for lopinavir; ritonavir (p = 0.004) 
o A prospective, randomized, controlled, open-label multicenter trial compared 
favipiravir (n = 116) against umifenovir [Arbidol] (n = 120) in treating patients with 
COVID-19; both treatments were given in combination with conventional 
therapy.(143) 
 No difference in clinical recovery rate at treatment Day 7 (61% for favipiravir 
vs. 52% for umifenovir; p = 0.1396; 95% CI: -0.0305 to 0.2213). 
o Additional data regarding clinical efficacy for COVID-19 are being evaluated.(132) 
• Safety Concerns: 
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o Contraindicated in pregnancy due to early embryonic death and teratogenicity 
observed in animal studies. 
 
Adjunctive/Supportive therapy: 
Anticoagulation: 
• Venous thromboembolism (VTE) prophylaxis with LMWH is recommended for all hospitalized 
patients with COVID-19 infection. Withhold VTE prophylaxis for active bleeding, platelet count 
less than 25 x 109/L, or fibrinogen less than 0.5 g/L.(80) (81) (91) (95) (102) 
o Use fondaparinux in patients with a history of heparin-induced thrombocytopenia.(95) 
o Use unfractionated heparin or reduced-dose LMWH in patients with creatinine 
clearance less than 30 mL/minute.(103) 
o Use mechanical thromboprophylaxis in patients where anticoagulants are 
contraindicated or unavailable.(95) 
o Data are insufficient to recommend for or against the use of increasing anticoagulant 
doses for VTE prophylaxis in hospitalized COVID-19 patients outside of a clinical 
trial.(133) 
o Hospitalized patients with COVID-19 should not routinely be discharged on VTE 
prophylaxis. Weighing the individual patient’s VTE risk factors and bleeding risk in 
addition to feasibility, consider extended thromboprophylaxis with a regulatory-
approved regimen (e.g., betrixaban, rivaroxaban) after discharge.(95) (133) 
 Aspirin could be considered for COVID-19 VTE prophylaxis if criteria for post-
discharge thromboprophylaxis are met.(95) 
o Elevated D-dimer has been noted in COVID-19 patients requiring hospitalization and 
has been associated with increased mortality. Limited data suggest a decrease in 
mortality in patients with severe COVID-19 infection or markedly elevated D-dimer 
concentrations (more than 6 times the upper limit of normal) who were given LMWH or 
heparin VTE prophylaxis.(80) (81) (91) (102) 
• Therapeutic-intensity anticoagulation is not recommended in the management of COVID-19 in 
the absence of confirmed or suspected VTE.(95) (128) 
o In patients already anticoagulated for VTE or atrial fibrillation, continue therapeutic 
anticoagulation. Consider withholding therapeutic anticoagulation in these patients for 
platelet count less than 50 x 109/L or fibrinogen less than 1 g/L.(102) 
o Treat all COVID-19 patients with confirmed or suspected VTE with therapeutic 
anticoagulation for at least 3 months. Therapeutic anticoagulation may be discontinued 
at 3 months if the patient has recovered from COVID-19 and has no ongoing risk 
factors for thrombosis or other indications for anticoagulation.(128) 
• Increasing the intensity of anticoagulation (i.e., from standard-intensity prophylaxis to 
intermediate-intensity prophylaxis or from intermediate-intensity prophylaxis to therapeutic-
intensity prophylaxis) may be reasonable in COVID-19 patients who experience recurrent 
clotting of access devices or extracorporeal circuits.(95) 
 
Azithromycin: 
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• Classification: Macrolide Antibacterial 
• Rationale for Use: Azithromycin may prevent bacterial superinfection, and macrolides may 
have immunomodulatory properties to work as adjunct therapy.(27) (34) (35) (36) (37) 
• Mechanism of Action: Macrolides may have immunomodulatory properties in pulmonary 
inflammatory disorders. They may downregulate inflammatory responses and reduce the 
excessive cytokine production associated with respiratory viral infections; however, their direct 
effects on viral clearance are uncertain. Immunomodulatory mechanisms may include 
reducing chemotaxis of neutrophils (PMNs) to the lungs by inhibiting cytokines (i.e., IL-8), 
inhibition of mucus hypersecretion, decreased production of reactive oxygen species, 
accelerating neutrophil apoptosis, and blocking the activation of nuclear transcription 
factors.(34) (35) (36) (37) 
• Evidence / Experience: 
o Due to the potential for toxicities, the NIH COVID-19 treatment guidelines recommend 
against the use of azithromycin in combination with hydroxychloroquine outside of 
clinical trials.(133) 
o In an open-label, non-randomized clinical trial of hydroxychloroquine (n = 26), 
azithromycin was administered in combination with hydroxychloroquine to prevent 
bacterial superinfection in 6 patients.(27) 
 Preliminary data suggest the potential for benefit as adjunct therapy. 
 On day 6, all patients treated with the combination (hydroxychloroquine and 
azithromycin) were virologically cured compared to 57.1% of patients treated 
with hydroxychloroquine alone (n= 20). 
o In a retrospective analysis of a multicenter cohort study (n = 349) in patients with 
MERS-CoV, 136 patients received macrolide therapy in combination with antiviral 
treatment.(28)  
 Macrolide therapy was not associated with a reduction in 90-day mortality 
compared to the control group (adjusted OR: 0.84; 95% CI: 0.47 to 1.51; p = 
0.56). 
 Sensitivity analysis excluding patients who received macrolides after day 3 
showed similar results (adjusted OR: 0.7; 95% CI: 0.39 to 1.28; p = 0.25). 
o A prospective review assessed virologic and clinical outcomes of 11 hospitalized 
patients who received hydroxychloroquine and azithromycin.(88) 
 Within 5 days, 1 patient died, 2 were transferred to the ICU, and 1 patient had 
therapy discontinued due to QT prolongation. 
 Nasopharyngeal swabs were still positive for SARS-CoV-2 in 8 of 10 patients 5 
to 6 days after treatment initiation. 
• Safety Concerns: (48) (49) 
o Risk of cardiac arrhythmias (e.g., QT prolongation) 
 Seriously ill patients with comorbidities have an increased risk of serious 
arrhythmias.(125) 
 Avoid other QT prolonging agents whenever feasible.(125) 
o Significant drug interactions 
 
Bronchodilators 
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• Most patients with COVID-19 do not need inhaled bronchodilator therapy. There is no role for 
inhaled bronchodilators in the management of COVID-19 unless the patient has underlying 
asthma or chronic obstructive pulmonary disease (COPD).(57) (61) 
o MDIs are preferred due to the potential for generation of aerosols that may increase 
the risk of viral transmission with nebulized therapy.(57) (61) 
o Due to concerns about supply chain interruption, some institutions are developing an 
MDI canister reassignment protocol to address potential shortages. An MDI canister 
reassignment protocol should emphasize hand hygiene and dual canister disinfection 
and avoid inadvertent sources of transmission.(57) (79) 
 
Corticosteroids: 
• Corticosteroid therapy is not recommended for viral pneumonia; however, use may be 
considered for patients with refractory shock or ARDS.(1) (7) (26) (62) (63) (64) (133) 
 
COVID-19 Convalescent Plasma: (22) 
• Classification: Plasma collected from persons who have recovered from COVID-19 that may 
contain antibodies to SARS-CoV-2 
• Rationale for Use: Clinical trials are being conducted to evaluate the use of COVID-19 
convalescent plasma to treat patients with severe or immediately life-threatening COVID-19 
infections. COVID-19 convalescent plasma is not intended for prevention of the infection.  
o To participate in these trials, investigators should submit requests to the FDA for 
investigational use under the traditional IND regulatory pathway. 
o In addition to clinical trials, licensed physicians may obtain COVID-19 convalescent 
plasma for an individual patient through the process of single patient eINDs. 
• Evidence / Experience: 
o Due to a lack of clinical data, the NIH COVID-19 treatment guidelines do not give 
recommendations for or against the use of convalescent plasma.(133) 
o In a case series of 5 critically ill patients with confirmed COVID-19 and ARDS, patients 
received convalescent plasma.(65) 
 Treatment: 2 consecutive transfusions of 200 mL to 250 mL of convalescent 
plasma (total dose: 400 mL) with a SARS-CoV-2-specific antibody (IgG) titer 
greater than 1:1,000 on the same day it was obtained from the donor. 
 Patient criteria included: 
• Severe pneumonia with rapid progression and continuously high viral 
load despite antiviral treatment 
• PAO2/FIO2 less than 300 
• Mechanical ventilation 
 After plasma infusion, body temperature normalized within 3 days in 4 of 5 
patients, Sequential Organ Failure Assess (SOFA) score decreased and 
PAO2/FIO2 increased within 12 days. 
 Viral loads decreased and became negative within 12 days after the transfusion 
with the SARS-CoV-2-specific ELISA and neutralizing antibody titers increased 
after the transfusion. 
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 ARDS resolved in 4 patients by day 12 after the transfusion and 3 patients were 
weaned from mechanical ventilation within 2 weeks of treatment. 
o In a case series of 6 critically ill patients with confirmed COVID-19 with abnormalities 
on chest CT (with the exception of 1 patient) who were deteriorating while receiving 
standard treatment, patients received convalescent plasma.(135) 
 Patients received at least 1 cycle (range, 1 to 3 cycles) of convalescent plasma 
(200 mL per cycle) over 30 minutes. 
 All patients had improved symptoms and chest CT and were discharged from 
the hospital. 
• Safety Concerns: (152) 
o Safety data from 5,000 hospitalized adults with severe or life-threatening COVID-19 
who received convalescent plasma (range: 200 to 500 mL) 
 36 serious adverse events (SAEs) within 4 hours of transfusion ( less than 1% 
of all transfusions) 
• 15 deaths (0.3% of all transfusions); 4 were attributed to treatment 
(possibly n = 3; probably n = 1; definitely n = 0) 
• 21 non-lethal SAEs 
o 7 transfusion-associated circulatory overload (TACO) and 11 
transfusion-related acute lung injury (TRALI);  all were attributed 
to treatment (possibly n = 9; probably n = 7; definitely n = 2) 
o 3 severe allergic transfusion reactions 
 Seven-day mortality rate was 14.9%. 
 
Fibrinolytics: 
• Rationale for Use: Severe COVID-19 infection is associated with coagulopathy, specifically a 
prothrombotic disseminated intravascular coagulation (DIC) with high rates of VTE, vascular 
occlusive events, and central line thrombosis and pulmonary congestion with microvascular 
thrombosis and occlusion observed on pathology. Fibrin deposition in the pulmonary 
microvasculature is a causative factor in the development of ARDS.(102) (136) 
• Mechanism of Action: Fibrinolytic agents act by converting plasminogen to plasmin on the 
surface of existing thrombi, thereby initiating local fibrinolysis.(137) 
• Evidence / Experience: 
o Alteplase: 
 In a case series of 3 critically ill patients with ARDS and respiratory failure, 
patients received alteplase followed by intravenous heparin.(136) 
• PaO2/FiO2 (P/F) ratio improved by 11% to 100% in all 3 patients; 
however, the improvements were transient. 
 Additional data regarding clinical efficacy for COVID-19 are being 
evaluated.(138) 
o Other fibrinolytics for which COVID-19 efficacy data are being evaluated include 
defibrotide.(139) (140) 
• Safety Concerns: (136) (137) 
o Bleeding 
Inhaled Pulmonary Vasodilators: 
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• There is no evidence for routine use of inhaled pulmonary vasodilators (e.g., nitric oxide, 
prostacyclins) in acute respiratory failure in COVID-19 patients. Avoid aerosolized 
vasodilators.(26) (60) (61) (133) 
• Use may be considered in specific patients with ARDS as a temporizing measure when 
patients develop refractory hypoxemia despite optimization of ventilation and other rescue 
strategies.(26) (60) 
• If inhaled pulmonary vasodilator therapy is used, a short trial with preestablished criteria for 
ongoing use or discontinuation is recommended.(26) (61) (133) 
• Additional data regarding clinical efficacy for COVID-19 are being evaluated.(58) (59) 
 
Interleukin-1 (IL-1) Antagonists: 
• Rationale for Use: Cytokine release syndrome may be a component of severe disease in 
COVID-19 patients.(24) (89) (90) (107) 
• Mechanism of Action: Interleukin-1 antagonists, such as anakinra and canakinumab, prevent 
the binding of IL-1 (a pro-inflammatory cytokine that mediates various inflammatory and 
immunological responses, including activation of IL-6) to interleukin-1 receptors. Anakinra acts 
similarly to the native interleukin-1 receptor antagonist by competitively inhibiting the binding of 
both IL-1 alpha and IL-1 beta to the IL-1 type 1 receptor. Canakinumab is a human monoclonal 
antibody that specifically targets and neutralizes IL-1 beta; thereby preventing its interaction 
with IL-1 receptors.(89) (106) (147) 
• Evidence / Experience: 
o Due to a lack of clinical data, the NIH COVID-19 treatment guidelines do not give 
recommendations for or against the use of IL-1 antagonists.(133) 
o Anakinra: 
 Retrospective cohort study comparing anakinra plus standard therapy to 
standard therapy alone in patients with COVID-19, moderate-to-severe ARDS, 
and hyperinflammation.(148) 
• 21-day survival was 90% in the anakinra group and 56% in standard 
treatment group (p = 0.009). Respiratory function improved in 72% (n = 
21/29) of anakinra patients and 50% (n = 8/16) of patients in the 
standard treatment group. 
 Additional data regarding clinical efficacy for COVID-19 are being 
evaluated.(132) 
o Other IL-1 antagonists for which COVID-19 efficacy data are being evaluated include 
canakinumab.(132) 
• Safety Concerns: (106) (147) 
o Caution in patients with thrombocytopenia and neutropenia 
o Infusion-related reactions (anakinra) 
 
Interleukin-6 (IL-6) Receptor Antagonists: 
• Rationale for Use: Cytokine release syndrome may be a component of severe disease in 
COVID-19 patients.(24) (25) (89) (90) 
Updated May 18, 2020 
Copyright © 2020 Elsevier 
 
• Mechanism of Action: IL-6 receptor-inhibiting monoclonal antibodies block IL-6-mediated 
signaling by competitively binding to both soluble and membrane-bound IL-6 receptors (sIL-6R 
and mIL-6R). IL-6 is a proinflammatory cytokine that is involved in diverse physiological 
processes such as T-cell activation, immunoglobulin secretion induction, hepatic acute-phase 
protein synthesis initiation, and hematopoietic precursor cell proliferation and differentiation 
stimulation. IL-6 is produced by various cell types, including T- and B-cells, lymphocytes, 
monocytes, and fibroblasts.(52) (72) (78) (97) (98) 
• Evidence / Experience: 
o Due to a lack of clinical data, the NIH COVID-19 treatment guidelines do not 
recommend for or against the use of IL-6 receptor inhibitors.(133) 
o Siltuximab: 
 A retrospective study of 21 patients with COVID-19 induced pneumonia/ARDS 
analyzed patients who received treatment with siltuximab.(101) 
• CRP concentrations reduced to within normal range by day 5 and 
remained stable in all 16 patients with available data; 33% (n = 7/21) 
condition improved with reduced need for ventilation; 43% (n = 9/21) 
condition stabilized; 24% (n = 5/21) condition worsened and required 
intubation. 
• A cohort study of patients treated with standard therapy is ongoing 
 Additional data regarding clinical efficacy for COVID-19 are being 
evaluated.(132) 
o Tocilizumab: 
 A retrospective review analyzed 21 patients in which tocilizumab was added to 
standard COVID-19 therapy.(25) 
• Preliminary data suggest tocilizumab may have clinical benefit as 
adjunctive therapy. 
• Clinical symptoms, CT opacity changes, lymphocyte percentage, and 
CRP concentrations all improved in these patients; however, no 
comparators were reported.  
 Some protocols include recommendations for use.(21) 
 Additional data regarding clinical efficacy for COVID-19 are being 
evaluated.(132) 
o Other IL-6 receptor inhibitors for which COVID-19 efficacy data are being evaluated 
include clazakizumab and sarilumab.(132) 
• Safety Concerns: (52) (78) (97) 
o Risk of GI perforation 
o Risk of hepatotoxicity 
o Caution in patients with thrombocytopenia and neutropenia 
o Infusion-related reactions 
 
Janus Kinase (JAK) Inhibitors: 
• Rationale for Use: Cytokine release syndrome may be a component of severe disease in 
COVID-19 patients.(24) (89) (90) (94) 
• Mechanism of Action: Janus kinases are intracellular enzymes that transmit signals arising 
from the interaction of cytokines and growth factors with receptors located on the cellular 
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membrane. These enzymes phosphorylate and activate signal transducers and activators of 
transcription proteins (STATs), which modulate intracellular activity including gene expression. 
The JAK-mediated signaling pathway is pivotal in influencing immune system activation, as 
cytokine receptors are expressed on most immune cells. JAK inhibitors modulate the signaling 
pathway by preventing the phosphorylation and activation of STATs.(92) (130) (131) 
• Evidence / Experience: 
o Due to the broad immunosuppressive effect, the NIH COVID-19 treatment guidelines 
recommend against the use of JAK inhibitors outside of clinical trials.(133) 
o Baricitinib: 
 A non-randomized, open-label trial compared safety and efficacy of baricitinib 
plus lopinavir; ritonavir in 12 patients with moderate COVID-19 against a control 
group treated with hydroxychloroquine plus lopinavir; ritonavir.(144) 
• For baricitinib-treated patients, all clinical characteristics and respiratory 
function parameters [i.e., fever, SpO2, PaO2/FiO2, CRP, Modified Early 
Warning Score (MEWS)] improved at weeks 1 and 2 compared to 
baseline. For control group, no significant changes were noted at week 
2 compared to baseline.  
• Preliminary results found no serious adverse events reported in the 
baricitinib-treated patients; however, 1 patient stopped treatment after 
10 days due to increased liver function test. 
 Additional data regarding clinical efficacy for COVID-19 are being 
evaluated.(132) 
o Other JAK inhibitors for which COVID-19 efficacy data are being evaluated include: 
ruxolitinib and tofacitinib.(132) 
• Safety Concerns: (92) (130) (131) 
o Thrombosis, including deep vein thrombosis (DVT) and pulmonary embolism (PE) 
o Risk of GI perforation 
o Caution in patients with neutropenia, lymphopenia, and anemia 
o Monitor for elevated liver function tests (LFTs) 
 
NSAIDs: 
• The NIH COVID-19 treatment guidelines recommend there be no difference in the use of 
antipyretic treatments (e.g., acetaminophen or NSAIDs) between patients with or without 
COVID-19. Patients taking NSAIDs for comorbid conditions should continue therapy as 
previously directed by their prescriber.(133) 
• ESICM and SCCM Surviving Sepsis Campaign recommendations suggest acetaminophen for 
temperature control in critically ill adults with COVID-19 who develop fever.(26)  
• The FDA continues to investigate the use of NSAIDs in patients with COVID-19 
symptoms.(20) 
• Concern for potential worsening of COVID-19 symptoms has been suggested, but 
confirmatory clinical data is lacking at this time.(5) 
• There is an anecdotal published letter that suggests a link between ibuprofen and increased 
ACE2 expression that may lead to worse outcomes in COVID-19 patients.(50) 
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Nutritional Supplements 
• The role of nutritional supplements for the treatment or prevention of COVID-19 is unknown. 
Several supplements are under investigation in combination with other treatment modalities 
(e.g. zinc, vitamin C, vitamin D) for both treatment and prophylaxis.(111) (112) (113) (114) 
(115) (116) (117) (118) (119) (120) 
• Safety concerns include adverse events from large doses and the potential for drug 
interactions.(108) (109) (110) 
 
 
Understanding of the treatment of patients with COVID-19 is rapidly evolving. Information will 
continue to emerge regarding pharmacologic therapy for SARS-CoV-2 as clinical data are 
reported.  
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